{"id":"W4401379890","doi":"10.1200/jco.2024.42.4_suppl.18","title":"CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Medicine; Docetaxel; Clinical endpoint; Internal medicine; Prostate cancer; Oncology; Hormonal therapy; Metastatic breast cancer; Enzalutamide; Androgen deprivation therapy; Taxane; Urology; Cancer; Randomized controlled trial; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001226053,0.001863772,0.002133588,0.0005458099,0.0004784872,0.001568941,0.001332592,0.001938881,0.01242266],"category_scores_gemma":[0.001101188,0.0007689031,0.001890754,0.0005249653,0.001160359,0.00110675,0.0003824399,0.003683936,0.002169834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001229478,"about_ca_system_score_gemma":0.002390563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002302458,"about_ca_topic_score_gemma":0.006180544,"domain_scores_codex":[0.999643,0.0001560474,0.00001340619,0.00006481788,0.00003023343,0.00009250326],"domain_scores_gemma":[0.999202,0.0001328586,0.0001301997,0.0000559571,0.00004326422,0.0004358145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9292139,0.03397819,0.001658156,0.0005585239,0.0007154723,0.00009197825,0.0001286662,0.0008817808,0.007983254,0.0001666755,0.002508196,0.02211514],"study_design_scores_gemma":[0.788837,0.2056533,0.002784971,0.00001982953,0.0002688438,0.00009305857,0.00003365919,0.0004451351,0.0006311796,0.0001278322,0.001089119,0.00001601455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852574,0.001731533,0.0005469568,0.0006287572,0.0002618308,0.004856208,0.003043404,0.0002864041,0.003387441],"genre_scores_gemma":[0.9789931,0.001529316,0.001630271,0.001624982,0.0003386374,0.005395657,0.003407398,0.00008137574,0.006999253],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01242266,"threshold_uncertainty_score":0.04155791,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1526407257271968,"score_gpt":0.5031225171413383,"score_spread":0.3504817914141414,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}